A 1-minute blood test detects decreased immune function and increased clinical risk in COVID-19 patients
© 2021. The Author(s)..
Upon infection with SARS-CoV-2, the virus that causes COVID-19, most people will develop no or mild symptoms. However, a small percentage of the population will become severely ill, and some will succumb to death. The clinical severity of COVID-19 has a close connection to the dysregulation of the patient's immune functions. We previously developed a simple, nanoparticle-enabled blood test that can determine the humoral immune status in animals. In this study, we applied this new test to analyze the immune function in relation to disease severity in COVID-19 patients. From the testing of 153 COVID-19 patient samples and 142 negative controls, we detected a drastic decrease of humoral immunity in COVID-19 patients who developed moderate to severe symptoms, but not in patients with no or mild symptoms. The new test may be potentially used to monitor the immunity change and predict the clinical risk of patients with COVID-19.
| Errataetall: |
ErratumIn: Sci Rep. 2021 Dec 21;11(1):24461. - PMID 34934132 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
Scientific reports - 11(2021), 1 vom: 06. Dez., Seite 23491 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Deb, Chirajyoti [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
7440-57-5 |
|---|
| Anmerkungen: |
Date Completed 15.12.2021 Date Revised 08.11.2023 published: Electronic ErratumIn: Sci Rep. 2021 Dec 21;11(1):24461. - PMID 34934132 Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41598-021-02863-2 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM334099145 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM334099145 | ||
| 003 | DE-627 | ||
| 005 | 20231226203937.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41598-021-02863-2 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1113.xml |
| 035 | |a (DE-627)NLM334099145 | ||
| 035 | |a (NLM)34873223 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Deb, Chirajyoti |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A 1-minute blood test detects decreased immune function and increased clinical risk in COVID-19 patients |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.12.2021 | ||
| 500 | |a Date Revised 08.11.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a ErratumIn: Sci Rep. 2021 Dec 21;11(1):24461. - PMID 34934132 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021. The Author(s). | ||
| 520 | |a Upon infection with SARS-CoV-2, the virus that causes COVID-19, most people will develop no or mild symptoms. However, a small percentage of the population will become severely ill, and some will succumb to death. The clinical severity of COVID-19 has a close connection to the dysregulation of the patient's immune functions. We previously developed a simple, nanoparticle-enabled blood test that can determine the humoral immune status in animals. In this study, we applied this new test to analyze the immune function in relation to disease severity in COVID-19 patients. From the testing of 153 COVID-19 patient samples and 142 negative controls, we detected a drastic decrease of humoral immunity in COVID-19 patients who developed moderate to severe symptoms, but not in patients with no or mild symptoms. The new test may be potentially used to monitor the immunity change and predict the clinical risk of patients with COVID-19 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Immunoglobulin G |2 NLM | |
| 650 | 7 | |a Gold |2 NLM | |
| 650 | 7 | |a 7440-57-5 |2 NLM | |
| 700 | 1 | |a Salinas, Allan N |e verfasserin |4 aut | |
| 700 | 1 | |a Zheng, Tianyu |e verfasserin |4 aut | |
| 700 | 1 | |a Middleton, Aurea |e verfasserin |4 aut | |
| 700 | 1 | |a Kern, Katelyn |e verfasserin |4 aut | |
| 700 | 1 | |a Penoyer, Daleen |e verfasserin |4 aut | |
| 700 | 1 | |a Borsadia, Rahul |e verfasserin |4 aut | |
| 700 | 1 | |a Hunley, Charles |e verfasserin |4 aut | |
| 700 | 1 | |a Abomoelak, Bassam |e verfasserin |4 aut | |
| 700 | 1 | |a Mehta, Vijay |e verfasserin |4 aut | |
| 700 | 1 | |a Irastorza, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Mehta, Devendra I |e verfasserin |4 aut | |
| 700 | 1 | |a Huo, Qun |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Scientific reports |d 2011 |g 11(2021), 1 vom: 06. Dez., Seite 23491 |w (DE-627)NLM215703936 |x 2045-2322 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2021 |g number:1 |g day:06 |g month:12 |g pages:23491 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41598-021-02863-2 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2021 |e 1 |b 06 |c 12 |h 23491 | ||